Partners

We apply our proprietary delivery platform technologies and expertise in pharmaceutics, drug delivery, and drug manufacture with the goal of minimizing the risk, time, and manufacturing cost of bringing the finished product to market.

Some of our product candidates have been partnered under drug development arrangements with third parties which provide for milestone and success fees, support for internal development costs, coverage of clinical trial costs, coverage of patent litigation costs, and royalties or profit sharing on product sales.

Our lead product candidate, a generic of Focalin XR, is partnered with Par Pharmaceutical Companies, Inc. (NYSE:PRX). Par markets generic drugs and innovative proprietary pharmaceuticals for specialty markets. According to IMS Health, Par ranks in the top 10 in U.S. sales among all generic drug companies.

Our Services
To meet the expectations of clients who demand the best pharmaceutical technology in the industry, and to ensure that we fulfill the most stringent development timeframes, we continue to develop in-house capabilities in controlled release products. These range from pre-formulation studies, design and development right through to regulatory approval.

Our services include life cycle management for products near or at the end of their patent life, and the enhancement of new chemical entities (NCEs). We continue to develop a wide array of products for exclusive licensing projects and are also seeking to bring late stage products to market.

In any partnership agreement we bring speed, technology and tenacity; we seek to use our intelligent drug delivery systems to position our products and those of our clients at the forefront of any controlled release market.

Our collaborative development and licensing agreements are based on the following:

  • Our proven track record
  • Our robust technology platform
  • The expertise of industry leaders
  • Our scientific breakthroughs

Once we have partnered, our purpose is simple: to provide breakthrough technology with rewards and results in a highly competitive timeframe.

For more information contact Mr. John Allport, VP of Licensing at jallport@intellipharmaceutics.com.